Md. Hakimul Haque | Microbiology | Best Researcher Award | 13596

Posted on by Research Awards

Dr. Md. Hakimul Haque | Microbiology | Best Researcher Award 

Dr. Md. Hakimul Haque | The University of Queensland | Australia

Dr. Md. Hakimul Haque is a research scientist with a PhD in Medicine from Griffith University, Australia, and over 19 years of academic and research experience in microbiology, molecular diagnostics, antimicrobial resistance, and cancer biomarker studies. He is currently a Postdoctoral Research Fellow at The University of Queensland and an Adjunct Research Fellow at James Cook University. Dr. Haque has authored 51 peer-reviewed publications, developed innovative biosensor technologies, and led multiple funded research projects on antimicrobial resistance and biosensing applications. His work integrates microbiology, nanotechnology, and translational research to advance diagnostic innovations and improve public health outcomes.

Author Profile 

Scopus

Education

Dr. Md. Hakimul Haque’s academic journey began with a strong foundation in veterinary medicine and microbiology, where he excelled as a top-performing student. His early interests lay in the study of infectious diseases and the molecular mechanisms that drive pathogen behavior. This curiosity pushed him towards advanced research on molecular detection methods, microbial pathogenesis, and antimicrobial resistance. His postgraduate studies further deepened his expertise, focusing on clinical microbiology, molecular diagnostics, and the application of innovative laboratory techniques. From the outset, Dr. Haque demonstrated not only scholarly excellence but also a passion for applying science to address pressing public health issues, particularly in infectious disease surveillance and diagnostics.

Experience

Building upon his academic foundation, Dr. Haque has pursued an extensive professional career spanning teaching, research, and clinical practice. He has served in various academic and scientific capacities, contributing both as a lecturer and as a mentor to postgraduate students. His transition to research-intensive roles has seen him work at the interface of microbiology, nanotechnology, and biomedical science. At The University of Queensland, he continues to engage in groundbreaking projects that explore biosensor development, biomarker extraction, and electrochemical diagnostics. His professional engagements have not only advanced his own expertise but have also fostered collaboration across disciplines, connecting veterinary science, human medicine, and bioengineering.

Research Focus

Dr. Haque’s research portfolio is both broad and impactful. His work centers on molecular diagnostics, antimicrobial resistance, and cancer biomarkers, with a particular emphasis on the development of biosensing technologies. By integrating microbiology with nanotechnology, he has pioneered innovative diagnostic tools that allow for rapid, sensitive, and cost-effective disease detection. His contributions extend to both human and animal health, reflecting a true “One Health” approach. Through the development of electrochemical biosensors and novel detection techniques, Dr. Haque has opened new pathways for identifying drug-resistant pathogens and cancer-related biomarkers, offering potential solutions to some of the most urgent challenges in global health. His more than 50 peer-reviewed publications and multiple book chapters highlight his scholarly productivity and commitment to advancing biomedical sciences.

 Accolades and Recognition

Throughout his career, Dr. Haque has been recognized for his excellence in both teaching and research. He has received multiple awards for high-impact publications, including recognition from prestigious organizations and international funding bodies. His academic success has been supported by competitive research scholarships, which enabled him to pursue advanced studies in Australia and conduct world-class research in cancer diagnostics and biosensing. In addition, he has been trusted with leadership roles in professional associations and review committees, where his expertise continues to shape scientific discourse and guide future research. These accolades reflect his dual strength as both a scientist and an academic leader.

Impact and Influence

The influence of Dr. Haque’s work extends far beyond academic publications. His studies on antimicrobial resistance directly inform public health strategies, especially in regions where resistant pathogens pose significant risks to human and animal health. His diagnostic innovations are designed to be practical and accessible, ensuring that advanced technologies can reach clinical and field settings worldwide. By mentoring graduate students, he has also contributed to capacity building in microbiology and biomedical sciences, nurturing the next generation of researchers. His collaborations with international partners reinforce his role as a global scientist whose work bridges disciplines, geographies, and societal needs.

Publications

First Molecular Characterization and Antibiogram of Bacteria Isolated from Dairy Farm Wastewater in Bangladesh.

Author: M. S. Islam, M. A. Polash, M. H. Hague
Journal: Veterinary medicine international
Year: 2025

Risk factors and antibiogram of human uropathogens in the northern part of Bangladesh: A crosssectional study.

Author: M. F. Islam, D. K. Das, M. H. Hague
Journal: Applied biology and biotechnology
Year: 2024

A simple, inexpensive and portable on-farm test for pregnancy diagnosis and ovary status in cows via chemical analysis of urine.

Author: M. H. Haque, S. Narayan, M. S. Islam
Journal: Biochemical and biophysical research communications
Year: 2023

Conclusion

Dr. Md. Hakimul Haque stands as a distinguished researcher whose journey reflects unwavering dedication to science, education, and global health. His pioneering work in molecular diagnostics, antimicrobial resistance, and biosensor technology has not only advanced biomedical research but also created tangible pathways for improving clinical outcomes. With a proven record of impactful publications, funded projects, and mentorship, he continues to shape the scientific community both in Australia and internationally. Looking to the future, Dr. Haque’s vision is clear—leveraging innovation and collaboration to address urgent health challenges and inspire the next generation of researchers. His career is a remarkable blend of academic brilliance, practical innovation, and a profound commitment to the betterment of society.

 

DEROSA LISA | Immunology and Microbiology | Best Researcher Award

Posted on by Research Awards

Assist Prof Dr. DEROSA LISA | Immunology and Microbiology | Best Researcher Award

MD, PhD at Gustave Roussy, France.

Associate Professor Dr. Lisa Derosa is a leading medical oncologist and researcher at Gustave Roussy Cancer Center (GRCC) in France, specializing in tumor immunology and cancer immunotherapy. With an MD from Pisa University and a PhD in Immunology from Paris-Sud University, she has significantly contributed to understanding the immunosuppressive role of antibiotics and the impact of gut microbiota on antitumor immunity. Since 2016, Dr. Derosa has pioneered research in these areas, earning numerous prestigious awards including the Conquer Cancer Foundation ASCO Merit Award and recognitions from ESMO and European Urology. She directs the ClinicoBiome Program at GRCC and co-directs the RHU Clinical Program Grant “Immunolife” and the EU Program Grant “Oncobiome.” Her research skills include clinical trial design, metagenomic analysis, immunological assays, and pharmacodynamic studies, making her a leader in microbiota-centered cancer therapies. Dr. Derosa’s collaborative approach and interdisciplinary projects have resulted in over 100 publications and significant advancements in cancer immunotherapy.

Professional Profiles:

Education

Associate Professor Dr. Lisa Derosa’s educational journey is marked by a series of prestigious degrees and certifications. In 2023, she became an Associate Professor of Immunology at Paris-Saclay University in France. Prior to that, in 2019, she earned her PhD in Immunology from Paris-Sud University and registered as a physician in France the same year. She also obtained a University Diploma in Animal Experimentation Level 1 from Sorbonne University, Paris, in 2018. Her earlier academic achievements include a Diplôme Universitaire Européen de Recherche Translationnelle Et Clinique en Cancérologie (DUERTECC) from Paris-Sud University and a Diplôme d’Université Carcinologie Clíniques (DUC) from Université Paris XI, both in 2016. Dr. Derosa completed her M2 in Pharmacology, Clinical Trial in Oncology at Pisa University in Italy in 2015 and became Board Certified in Medical Oncology from the same university in 2014. She first qualified as a physician in Italy in 2009, following her MD from the School of Medicine at Pisa University in 2008.

Professional Experience

Associate Professor Dr. Lisa Derosa has a distinguished career in medical oncology and cancer immunology. Since 2022, she has been serving as the Co-Coordinator of the RHU IMMUNOLIFE (PIA2) multi-team program project in France and as a member of the Scientific Advisory Board for everImmune. In the same year, she was appointed as an Associate Professor of Immunology at Paris-Saclay University and a Senior Research Associate in the Cancer Immunology Department at Gustave Roussy Cancer Center (GRCC). Dr. Derosa has also been the Clinical Director of the ClinicoBiome Program at GRCC since 2020 and has held the position of Medical Oncology Specialist at GRCC since 2020. From 2017 to 2021, she co-coordinated the PIA2 RHU TORINO LUMIERE project. She has also been a Co-Coordinator of the H2020 ONCOBIOME project since 2019. Prior to these roles, Dr. Derosa served as a clinical attending in the Genitourinary and Lung Department at GRCC from 2019 to 2020 and completed a clinical fellowship in the Genitourinary Medical Oncology Department at GRCC from 2016 to 2019. Before joining GRCC, she was a clinical attending in the Oncology Department at Hospital S. Chiara-Pisa from 2014 to 2016. Additionally, she gained valuable experience as a visiting student at GRCC in 2013 and at the Oncology Department at Ospedali Riuniti di Livorno from 2006 to 2008.

Award and Honors

Associate Professor Dr. Lisa Derosa has received numerous prestigious awards and honors throughout her career, reflecting her significant contributions to oncology and immunology. In 2023, she was honored with the Conquer Cancer Foundation ASCO Merit Award. The previous year, she received an accolade from the European Society for Medical Oncology (ESMO) at their Asia Annual Meeting. In 2021, she was awarded the Best Scientific Paper published on Fundamental Research by European Urology and also received the ASCO Merit Award in Lung Cancer, supported by Frances A. Shepherd. Her exceptional work earned her the EATI Award in 2020. The year 2018 was particularly notable, as she received the Best Paper Award from ESMO YOC, the ESMO Annual Meeting Award, the Early Detection of Cancer Conference Award from ARC, and the Conquer Cancer Foundation ASCO Merit Award. In 2017, she was recognized with multiple Conquer Cancer Foundation ASCO Merit Awards, including the Genitourinary Cancer Merit Award. In 2016, she was the recipient of the 5th Pieter de Mulder Memorial Prize and the ESMO Translational Research Fellowship Award. Her early career was distinguished by the AIOM Award for young researchers in Oncology in 2015, the ESMO Annual Meeting Award in 2014, and the ITT Stage in Oncology Award from the Istituto Toscano Tumori in 2013.

Research Interest

Associate Professor Dr. Lisa Derosa’s research interests lie at the intersection of tumor immunology and cancer immunotherapy, with a particular focus on the immunosuppressive role of antibiotics in cancer treatment and the impact of gut microbiota on antitumor immunity. Since 2016, she has been pioneering research in these areas, exploring how the composition of gut microbiota can regulate the effectiveness of immune checkpoint inhibitors. Her innovative work has led to significant insights into the microbiota’s role in cancer treatment, making her a leading figure in the development of microbiota-centered interventions. Dr. Derosa currently directs the Microbiota-Centered Intervention Program (ClinicoBiome) at Gustave Roussy Cancer Center and co-directs the RHU Clinical Program Grant “Immunolife” as well as the EU Program Grant “Oncobiome.” Her research continues to bridge clinical oncology with translational research, aiming to improve patient outcomes through a deeper understanding of the immune system’s interactions with cancer therapies.

Research Skills

Associate Professor Dr. Lisa Derosa possesses a comprehensive skill set in the field of cancer immunology and immunotherapy, characterized by her expertise in clinical and translational research. She has extensive experience in designing and conducting clinical trials, particularly those investigating the interactions between gut microbiota and immune checkpoint inhibitors. Dr. Derosa is skilled in metagenomic analysis, allowing her to identify microbiome-based biomarkers that predict patient response to immunotherapy. Her proficiency in immunological assays and molecular biology techniques has been instrumental in her research on the immunosuppressive effects of antibiotics and the regulatory role of gut microbiota in antitumor immunity. Additionally, she has a strong background in pharmacodynamic and pharmacokinetic studies, which she has applied in various phase II clinical trials. Dr. Derosa’s ability to integrate clinical data with cutting-edge laboratory research has made her a leader in the development of microbiota-centered cancer therapies. Her collaborative projects often involve multidisciplinary teams, highlighting her skills in project management and scientific communication.